Quarterly report pursuant to Section 13 or 15(d)

CONDENSED BALANCE SHEETS

v3.19.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 5,909 $ 9,295
Restricted cash 0 361
Receivables 2,052 1,737
Inventory 1,246 1,262
Contract assets 0 99
Prepaid expenses and other current assets 882 547
Total current assets 10,089 13,301
Property and equipment, net 782 794
Operating lease right-of-use asset 569 0
Total assets 11,440 14,095
Current liabilities:    
Accounts payable 1,204 1,526
Accrued clinical trials expenses 666 620
Accrued sales allowances 887 0
Other accrued liabilities 534 466
Deferred revenue 0 313
Operating lease liability, current 243 0
Current portion of long-term debt 1,227 527
Total current liabilities 4,761 3,452
Operating lease liability, non-current 357 0
Long-term debt 3,242 3,787
Derivative liability 25 25
Total liabilities 8,385 7,264
Stockholders' equity:    
Common stock, at amounts paid-in 13 13
Additional paid-in capital 340,138 339,397
Accumulated deficit (337,096) (332,579)
Total stockholders' equity 3,055 6,831
Total liabilities and stockholders' equity $ 11,440 $ 14,095